Patents by Inventor Zbigniew Pietrzkowski

Zbigniew Pietrzkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090203638
    Abstract: Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and dyslipidemia. In still further preferred aspects, compounds with cytokinin activity are used to activate AMPK and/or Akt. Consequently, various diseases associated with dysregulation of AMPK and/or Akt may be treated using the compounds of the present inventive subject matter.
    Type: Application
    Filed: April 7, 2009
    Publication date: August 13, 2009
    Applicant: VDF FUTURECEUTICALS, INC.
    Inventors: Dusan Miljkovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski
  • Publication number: 20090098225
    Abstract: Dicot, and especially Brassicaceae sprout preparations are employed as a dietary agents that significantly reduce oxidized species in human serum. In one especially preferred aspect, contemplated compositions are employed to reduce serum oxLDL and to increase serum HDL levels.
    Type: Application
    Filed: May 24, 2006
    Publication date: April 16, 2009
    Applicant: VDF FUTURECEUTICALS, INC.
    Inventor: Zbigniew Pietrzkowski
  • Publication number: 20080268429
    Abstract: Contemplated compositions and methods are directed to the use of microvesicles from an optionally recombinant donor cell to impart a desirable effect to a recipient cell. In certain preferred aspects, RNA of the microvesicles is employed to achieve the desirable effect. For example, microvesicles are used in vitro to increase the number of passages of a cell growing in a medium, reduce serum and/or growth factor requirements of a cell growing in a medium, and/or delay differentiation of a cell growing in a medium. Further preferred aspects include use of the microvesicles as therapeutic agents in which RNA, a membrane protein, and/or a cytosolic protein encapsulated in or coupled to the microvesicle provide a therapeutic effect. Additionally, diagnostic methods are contemplated in which RNA of a microvesicle isolated from a mammal is associated with a condition of the mammal.
    Type: Application
    Filed: March 30, 2005
    Publication date: October 30, 2008
    Applicant: SOURCEPHARM, INC.
    Inventor: Zbigniew Pietrzkowski
  • Patent number: 7320806
    Abstract: Compositions and methods are provided to increase glucose uptake in a cell as well as to treat a patient suffering from a condition or disorder associated with AMPK regulation. Particularly contemplated compositions include a compound that is isolated from a plant that has AICAR-like activity. In another aspect of the invention, contemplated compositions comprise a non-insulin compound that has AICAR-like activity and activates AMPK in a cell.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: January 22, 2008
    Assignee: VDF Futureceuticals, Inc.
    Inventors: Dusan Miljkovic, Zbigniew Pietrzkowski
  • Publication number: 20070184067
    Abstract: Contemplated food products include compounds with cytokinin activity to modulate glucose and/or lipid metabolism, and in especially preferred aspects contemplated food products include one or more naturally occurring cytokinins (e.g., kinetin, N2-acetylguanine, zeatin, dihydrozeatin) at a concentration effective to prevent or treat pre-diabetes, insulin resistance, type-2 diabetes, syndrome X, and/or dyslipidemia. Methods of marketing such products are also contemplated.
    Type: Application
    Filed: August 3, 2004
    Publication date: August 9, 2007
    Inventors: Dusan Miljkovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski, John Hunter, Jeff Van Drunen
  • Publication number: 20070161582
    Abstract: Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and dyslipidemia In still further preferred aspects, compounds with cytokinin activity are used to activate AMPK and/or Akt. Consequently, various diseases associated with dysregulation of AMPK and/or Akt may be treated using the compounds of the present inventive subject matter.
    Type: Application
    Filed: August 5, 2004
    Publication date: July 12, 2007
    Inventors: Dusan Mijikovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski
  • Patent number: 7081449
    Abstract: A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2?, C3?, C4? and/or C5? position. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both purine nucleoside analogs and the corresponding prodrugs are employed in the reduction of growth of neoplastic cells.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: July 25, 2006
    Assignee: Valeant Research & Development
    Inventors: Zbigniew Pietrzkowski, Guangyi Wang, Johnson Lau, Zhi Hong, Jean-Luc Girardet, Esmir Gunic
  • Publication number: 20060134240
    Abstract: Compositions and methods are provided to increase glucose uptake in a cell as well as to treat a patient suffering from a condition or disorder associated with AMPK regulation. Particularly contemplated compositions include a compound that is isolated from a plant that has AICAR-like activity. In another aspect of the invention, contemplated compositions comprise a non-insulin compound that has AICAR-like activity and activates AMPK in a cell.
    Type: Application
    Filed: August 29, 2003
    Publication date: June 22, 2006
    Inventors: Dusan Miljkovic, Zbigniew Pietrzkowski
  • Publication number: 20060029642
    Abstract: Complex metal-containing matrices, and especially chromium-containing matrices are produced from a water soluble preparation that is derived from an item suitable for animal (and most typically human) consumption. In particularly contemplated aspects, the water soluble preparation is an extract or filtrate of disintegrated brewer's yeast, and the so prepared complex mixture is combined with a chromium-3+ ions.
    Type: Application
    Filed: January 12, 2005
    Publication date: February 9, 2006
    Inventors: Dusan Miljkovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski
  • Publication number: 20040170705
    Abstract: Compositions and methods are provided to increase glucose uptake in a cell. Particularly contemplated compositions include a compound that is isolated from a plant that has AICAR-like activity. In another aspect of the invention, contemplated compositions comprise a non-insulin compound that has AICAR-like activity and activates AMPK in a cell.
    Type: Application
    Filed: April 20, 2004
    Publication date: September 2, 2004
    Inventors: Dusan Miljkovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski
  • Publication number: 20030144502
    Abstract: A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2′, C3′, C4′ and/or C5′ position. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both purine nucleoside analogs and the corresponding prodrugs are employed in the reduction of growth of neoplastic cells.
    Type: Application
    Filed: December 31, 2002
    Publication date: July 31, 2003
    Inventors: Zbigniew Pietrzkowski, Guangyi Wang, Johnson Lau, Zhi Hong, Jean-Luc Girardet, Esmir Gunic
  • Patent number: 6080425
    Abstract: Boron compounds/complexes, other than boric acid and boric acid salts, are utilized for rejuvenating of skin. The compounds/complexes have a central tetrahedral boron atom covalently bound to four ligands, which may be either identical or different from each other. Preferred ligands include an oxygen, nitrogen, carbon or sulfur atom, and more preferred ligands are saccharides or amino acids that form stable five- or six-membered rings with the boron atom. Especially preferred compounds have a dissociation constant of at least 3,000, and include a saccharide. Especially preferred complexes include a sodium, potassium, magnesium or calcium cation. The compounds/complexes are useful in rejuvenating skin, including decreasing skin wrinkles, improving skin thickness, increasing skin hydration, softness and elasticity, improving the skin color, and decreasing the number and size of age spots.
    Type: Grant
    Filed: November 16, 1998
    Date of Patent: June 27, 2000
    Assignee: TopGene, Inc.
    Inventors: Dusan Miljkovic, Zbigniew Pietrzkowski
  • Patent number: 6017898
    Abstract: Oligonucleotides are provided which are effective in inhibiting the growth, metastasis and/or angiogenesis of tumors, including particularly melanoma and/or lung cancer. Methods are also provided for use of these oligonucleotides in the treatment of diseases.
    Type: Grant
    Filed: April 6, 1998
    Date of Patent: January 25, 2000
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Zbigniew Pietrzkowski, Dariusz Cieslak, Gordana Olbina
  • Patent number: 5990299
    Abstract: Neoplastic cells which over-express CD44, including especially non-small cell lung cancer and melanoma cancer cells, are treated with antisense oligonucleotides to control CD44 expression. Test results show that the claimed oligonucleotides significantly decreases cell growth in a CD44 sequence specific manner of lung cancer or melanoma cells, or both, but are largely non-toxic to normal cells. Examples of dosing in a clinical setting are provided.
    Type: Grant
    Filed: August 14, 1995
    Date of Patent: November 23, 1999
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Sabera Ruzdijic, Zbigniew Pietrzkowski, Dariusz Cieslak
  • Patent number: 5849903
    Abstract: Oligonucleotides are provided which are effective in inhibiting the growth, metastasis and/or angiogenesis of tumors, including particularly melanoma and/or lung cancer. Methods are also provided for use of these oligonucleotides in the treatment of diseases.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: December 15, 1998
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Zbigniew Pietrzkowski, Dariusz Cieslak, Gordana Olbina
  • Patent number: 5723589
    Abstract: Methods and compositions are provided which increase the cellular uptake of bioactive materials by covalently bonding such compounds to carbohydrate moieties through chemical linkers using other than glycosidic bonds. Numerous carbohydrates, linkers and bioactive materials can be joined in this way to form novel compositions, which are collectively referred to herein as glinkosides. Preferred glinkosides are preferentially taken up by glucose receptor and/or other cellular receptors, and once inside the cells, the glinkosides are cleaved into a sugar, a linker or linker fragments, and a biologically active compound. Various aspects of the invention include processes for synthesizing glinkosides, glinkoside compositions, and methods of treating diseases using glinkosides.
    Type: Grant
    Filed: December 21, 1995
    Date of Patent: March 3, 1998
    Assignee: ICN Pharmaceuticals
    Inventors: Dusan Miljkovic, Zbigniew Pietrzkowski, Esmir Gunic, Wilfried Seifert